ERBB2 and neoplasm: Compared with the reference model of clinical factors, including age at diagnosis, tumor size, lymph node involvement, grade, hormone receptor, and HER2 status, the model with the addition of unfavorable genotypes improved the predictive capability for iDFS (AUC = 0.732, 95% CI = 0.702–0.761, p = 0.006, Figure 2A), DDFS (AUC = 0.735, 95% CI = 0.705–0.764, p = 0.004, Figure 2B), BCSS (AUC = 0.742, 95% CI = 0.710–0.773, p = 0.029, Figure 2C), and OS (AUC = 0.733, 95% CI = 0.702–0.765, p = 0.019, Figure 2D).